Spring Bank Pharmaceuticals developing hepatitis b vaccine

Spring Bank Pharmaceuticals, an IND-stage drug discovery company, has been awarded an RO1 grant from the National Institute of Health, National Institute of Allergy and Infectious Disease to develop a novel hepatitis B virus treatment.

"We are very pleased to receive this important grant award from the NIH to further develop SB 9200 for the treatment of Hepatitis B virus infections," Douglas Jensen, CEO of Spring Bank Pharmaceuticals, said. "Hepatitis B infection is very widespread and has proven to be a very difficult disease to treat. The NIH has made it clear that new types of drugs to treat Hepatitis B, such as SB 9200, are urgently needed."

SB 9200 is an orally bioavailable agent that is meant to treat Hepatitis B virus infections. The drug has both direct antiviral and immune stimulating activities and acts via a novel host target. According to Spring Bank, the drug is well tolerated and can be used in combination with other classes of antivirals.

Under the terms of the award, Spring Bank Pharmaceuticals will receive $3.9 million over the course of five years to support development efforts of SB 9200. The company has received three previous federally funded grant rewards, which brings the company’s total federal support to over $12 million.

"The NIH support for our HBV program validates our novel approach to treat this widespread disease,” R.P. Iyer, chief scientific officer of Spring Bank Pharmaceuticals, said. “SB 9200 holds great promise because it is a new class of potent orally bioavailable drug that works by an entirely novel mechanism of action and has demonstrated an excellent safety profile in a battery of in vitro and in vivo toxicology studies."